Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)

NCT03383094 is registered in ClinicalTrials.gov with Loren Mell, MD as lead sponsor.

NCT NCT03383094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03383094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Lead sponsor
Loren Mell, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 15, 2018
Completion date
December 31, 2027
Enrollment
126 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of head and neck, cancer, advanced, cancer, metastatic, head and neck squamous cell carcinoma, oral cancer, oropharyngeal cancer, oropharynx cancer, oropharynx cancer, metastatic, oropharynx cancer, recurrent, oropharynx cancer, stage iii, tumor, tumor metastasis, tumor neck, tumor recurrence